Le Lézard
Classified in: Health
Subjects: WOM, FDA

JayMac Pharmaceuticals' EnBrace HRtm Clinical Study Finds Rx Prenatal Vitamin Treats and Prevents Depression in Women Before and During Pregnancy

LAFAYETTE, La., Feb. 26, 2019 /PRNewswire/ -- Women who struggle with depression during and around the time of pregnancy frequently opt to discontinue the use of antidepressants due to the possible risks to the fetus, putting themselves at jeopardy for depression relapse. Outcomes from the newly released Massachusetts General Hospital (MGH)/Harvard pilot clinical trial of JayMac Pharmaceuticals' EnBrace HRtm for the treatment of women seeking antidepressant alternatives for Major Depressive Disorder (MDD) in anticipation of or during pregnancy verify that EnBrace HR is an effective alternative. Women wanting to discontinue or minimize the use of antidepressants no longer need to choose between the safety of their baby and treatment of their depression.

The efficacy observed in this study confirms that Rx EnBrace HR, an all-natural, nutritional prenatal vitamin with methylfolate, is an effective, safe option for treating and preventing depression in pregnancy and was well tolerated by patients. The findings from the clinical trial were published online this month in Annals of Clinical Psychiatry.

In this study, EnBrace HR was investigated for depressive relapse prevention and for acute treatment of MDD in women planning pregnancy or during pregnancy. The study notes there is an evidence base for the antidepressant effects of the shared interconversion of folic acid, folinic acid and methylfolate, as found in EnBrace HR, showing significant improvement in perinatal depressive symptoms and providing a new treatment option for depression in pregnancy. Perinatal depression has been a critical public health concern and therapeutic dilemma for practitioners for years.

MGH Center for Women's Mental Health states in its February 6, 2019 blog post that, "This pilot study suggests that EnBrace HR may be helpful for not only for preventing depressive relapse during pregnancy but may also have antidepressant effects....  While this was a small study, these results are exciting and we look forward to seeing more studies with EnBrace HR and similar compounds for women who are at risk for depression during pregnancy."

JayMac Pharmaceuticals develops natural, evidence-based, root-cause treatments for psychiatric disorders that address genetic insufficiencies. Follow this link for the complete release (PDF). For additional information, visit http://www.enbracehr.com/ or call 985-788-7755.

Media Contact:
Laura Luthi



These press releases may also interest you

4 jui 2020
SummaryProducts: Cetrotide 0.25mg Issue: One lot of Cetrotide 0.25mg is being recalled because some vials may have missing stoppers, which could make the product unsterile. What to do: Check the lot number on your product or contact your pharmacist...

4 jui 2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 105,091 cases of COVID-19 in Canada, including 8,663 deaths. 65% of people have now recovered....

4 jui 2020
The latest data of the evolution of COVID-19 in Québec reveal 102 new cases over the past 24 hours, bringing the total number of people infected to 55,784. During the same period, 3 new deaths were recorded, to which are added 3 deaths that occurred...

4 jui 2020
On Friday, the British government announced that, as of July 10th, those travelling from the Commonwealth of Dominica to England need not self-isolate for 14 days. Dominica is one of the 59 countries and 14 British Overseas Territories forming a...

4 jui 2020
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...

4 jui 2020
Gilead Sciences, Inc. today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed...

News published on 26 february 2019 at 08:45 and distributed by: